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Abstract This paper on the biological tests carried
out on serum/plasma samples from donors of human
body material (HBM) is the result of a project of the
working Group of Superior Health Council of Belgium
formed with experts in the field of HBM and infectious
serology. Indeed, uncertainty about the interpretation
of biological test results currently leads to the
sometimes unjustified cancelling of planned donations
or the rejection of harvested HBM, whilst more
sophisticated diagnostic algorithms would still allow
the use of organs or HBM that would otherwise have
been rejected. NAT tests will not be discussed in this
publication. In the first part some general aspects as
the need for a formal agreement between the Tissue
Establishment l and the laboratory responsible for the
biological testing, but also some specifications regard-
ing testing material, the choice of additional biological
tests, and some general aspects concerning interpre-
tation and reporting are discussed. In a second part,
detailed information and recommendations
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concerning the interpretation are presented for each of
the mandatory tests (human immunodeficiency virus,
hepatitis B virus, hepatitis C virus and syphilis) is
presented. A number of not mandatory, but regularly
used optional serological tests (e.g. for the detection of
antibodies to Toxoplasma gondii, Epstein–Barr virus,
human T cell leukemia virus and cytomegalovirus) are
also extensively discussed. Although the project was
meant to provide clarification and recommendations
concerning the Belgian legislation, the majority of
recommendations are also applicable to testing of
donors of tissues and cells in other (European)
countries.
Keywords Reporting  Interpretation  Biological
test  Donor of human body material
Introduction
The directive 2004/23/EC, 2006/17/EC, 2006/86/EC
and annex 28 of EU mapping of blood donor testing
requirements (2015) have been transposed in Belgian
regulation.
The Royal Decree (RD) of 28 September 2009
setting standards of quality and safety for the donation,
harvesting, procurement, testing, processing, storage
and distribution of human body material that the banks
for human body material, the intermediary structures
and the production establishments must comply with,
describes, among other things, the biological tests that
need to be carried out among living and deceased
donors.
For some serological parameters, interpreting their
results may turn out to be a complex issue, giving rise
to doubts and/or uncertainties.
Uncertainty about the interpretation of serological
test results currently leads to the sometimes unjustified
cancelling of planned donations or the rejection and
destruction of harvested HBM, whilst more sophisti-
cated diagnostic algorithms would still allow the use
of tissues that would otherwise have been rejected.
In the current paper, members of the working group
in ‘‘cells, tissues and organs of human and animal
origin’’ of the Superior Health Council (SHC) have
examined both the mandatory serological tests as
defined in Royal Decree of 28th of September 2009,
(antibodies against human immunodeficiency virus
(anti-HIV)-1,2; Hepatitis B surface antigen (HBsAg),
antibodies against Hepatitis B core antigen (anti-HBc),
antibodies against Hepatitis C virus (anti-HCV) and
the syphilis screening test) as well as optional
serological tests (antibodies against cytomegalovirus
(anti-CMV), antibodies against Toxoplasma gondii
(anti-Toxoplasma), antibodies against Epstein–Barr
virus (anti-EBV), antibodies against human T-cell
leukemia virus (anti-HTLV)) in the process of selec-
tion of the HBM donors. Other potential optional tests,
mainly those for the testing of specific infectious
agents, non-endemic in Europe, in a temporary
epidemiological context (e.g.West Nile virus, Chikun-
gunya, Ebola, Zika are not discussed in the current
paper). In all cases, this concerns optional tests, which
are often only relevant during a specific period of time,
i.e. when there is an increased prevalence of the
infection in question and will imply the use of highly
specialized tests performed in specific laboratories.
This paper does not deal with any other tests than
those mentioned above. It focusses on the interpreta-
tion and reporting of serological tests carried out
within the legal framework of the Royal Decree of 28
September 2009. It does not consider these tests for
diagnostic purposes.
General considerations
Agreement between the institution involved
in the donation, harvesting, procurement, testing,
processing, storage and distribution of HBM
and the laboratory responsible for the biological
testing on samples from HBM donors (laboratory)
Prior to transferring the samples to the laboratory that
will undertake the biological testing as part of the
HBM donation process, an agreement needs to be
signed between the HBM bank concerned and the
laboratory. At the very least, the latter should clarify
the methodology of the tests used by the laboratory,
the expected turnaround time for the assays and the
agreements related to the reporting of the results.
D. Goossens
Red Cross, Namur, Belgium
G. Hanssens
Sint-Genesius-Rode, Belgium
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Source material
The biological tests are carried out on donor serum or
plasma. They are not to be performed on other fluids or
secretions such as aqueous or vitreous humor, unless
specifically justified clinically using a validated test
for such other fluid (2006/17/EC). The biological tests
cannot be performed on the HBM itself.
While venous puncture represents a standard blood
collection method, use of arterial and intracardiac
blood can be justified (Baleriola et al. 2012; Kitchen
et al. 2013).
Blood samples may come from living or deceased
donors In case of a living donor, the sample should be
collected at the time of or shortly after donation (max.
7 days). This implies the possibility to collect and test
an extra sample or retest on a later time point if
needed. In case of a deceased donor, this possibility
does not exist
The blood samples must have been taken within
48 h prior to death. If this is not possible, the sample
needs to be taken as soon as possible and in any event
within 24 h after death. The time since death may
affect the reliability of the tests, hence the importance
of using an ante-mortem sample whenever possible,
unless the test has been validated for post-mortem
blood samples.
In the case of neonate or infant donors less than
1 year of age, positive serological results (IgG) do not
necessarily represent actual infection of the donor, as
these antibodies can be passively transmitted and be of
maternal origin. In such case, lack of the presence of
IgM antibodies, and possibly additional testing using
PCR, may allow to rule out the infection of the donor.
As stated in the regulations, if a transfusion was
administered shortly before donation, haemodilution
may have occurred, which needs to be taken into
account because major dilution is liable to lessen the
detectability of the antibodies or antigens in the donor
blood. The results can also be invalid due to treatment
with immunosuppressive agent (2006/17/EC).
Testing must be carried out on individual samples.
Choice of additional biological tests
Apart from the mandatory tests, further tests may be
decided upon as well. The decision whether or not to
run optional tests depends on the type of tissue
(infectious organisms may be present in some tissues
and not in others) and the donor.
When tests are carried out on post-mortem samples
the serological method used must have been validated
for this type of samples by the producer or by the
laboratory that performs the test in the event of there
being no certification available from the producer.
Samples from deceased HBM donors need to be
analysed using tests that have been validated by the
producer or by the laboratory performing them in the
event of there being no certification available from the
producer for use on post-mortem samples.
Test interpretation and implications
for the releasing or rejecting of HBM
If the test results are positive for mandatory tests, the
HBM will usually be rejected.
In some cases (e.g. a combination of positive results
for anti-HBc and anti-HBs and negative results for
HBsAg), the HBM can still be released, since this
combination of results points to a past infection and
immunity.
In some very specific cases, the results of a
screening test may be overridden by a confirmatory
test. This is only possible under certain conditions,
which will be discussed below for each of the tests
concerned.
In the case of autologous donations or donations
between partners for medically assisted procreation
(MAP) purposes, HBM from donors with positive test
results may be released.
If viral inactivation steps are applied during
processing (for example ensuring the safety of bone
tissue), the serological results should be negative. So,
as regard for living donors, NAT testing will not be
performed and there is no need to repeat the test when
the processing includes an inactivation step that has
been validated for the infectious agents concerned.
As regards deceased donors, the tests to run include,
at the very least: NAT screening for HIV, NAT
screening for HCV and NAT screening for HBV,
unless the processing includes an inactivation step that
has been validated for the infectious agents concerned.
Communicating the results of the tests
The royal decree of 28th of September 2009 setting the
quality and safety norms indicates that the confirmed
123
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results of the donor assessment shall be communicated
and clearly explained to the latter, taking into account
the privacy requirements (Section 9, § 4, of the Act of
22 August** 2002). The information shall preferably
be transferred via the attending physician or the
general practitioner. The laboratory contact informa-
tion shall be sent to the attending physician or general
practitioner for any further questions regarding the
results.
Mandatory biological tests
The R.D. of 28 September 2009 mentioned above
implementing a.o. the DIRECTIVE 2006/17/EC sets
out mandatory biological tests that need to be
performed on samples from HBM donors. At the very
least, the following tests need to be performed:
a. As regards living donors: anti-HIV 1,2; HBsAg,
anti-HBc; anti-HCV and the syphilis screening
test. When HBM from living donors that is
intended for allogeneic use can be stored for
extensive periods of time, repeat samples should
be taken and retested after a period of 180 days.
The repeat samples are aimed at reducing the
window-phase of possible infection. If, in the case
of a living donor, the sample of the donation, as
defined above, it also tested bymeans NAT testing
for HIV, HBV and HCV there is no need for repeat
samples. Similarly, there is no need to repeat the
test when the processing includes an virus inac-
tivation step that has been validated for the
infectious agents concerned.
b. As regards deceased donors, the tests to run
include, at the very least, those listed under
paragraph A, as well as: NAT screening for HIV,
HCV and for HBV, unless the processing includes
an inactivation step that has been validated for the
infectious agents concerned. Furthermore, back-
screening of receptors of organs obtained from the
same donor can provide additional safety.
Under certain circumstances, the donor history and
specific features of the HBM intended for donation
(e.g. malaria, CMV, toxoplasmosis) may require
further testing. In part 3 of these recommendations,
some of these optional tests including anti-CMV, anti-
Toxoplasma, anti-EBV and anti-HTLV will be
described more in detail.
Biological tests for the detection of HIV
antibodies/viral genome
HIV 1/2 antibodies (anti-HIV 1/2)
Serological screening tests for anti-HIV 1/2 are among
the routine tests that are carried out in most diagnostic
laboratories in Belgium. The strict regulations in place
for the producers of these tests contributed to the
placing on the Belgian market of high- performance
and high-quality tests. As a result, there are usually no
major difficulties when running or interpreting these
tests.
Non-negative (grey area and reactive) screening
results for anti-HIV-1/2) need to be confirmed by one
of the recognised Belgian AIDS Reference Laborato-
ries (ARLs).
Depending on the type of HBMdonations, this most
often primarily involves interpreting and reporting the
results of the screening tests, given the fact that the
confirmatory tests that are currently used cannot be
carried out in an emergency situation.
HIV 1/2-screening assays are traditionally subdi-
vided into distinct ‘‘generations’’ according to the
different principles on which they are based. As
regards the serological immunoassays that are used for
anti-HIV-1 screening, the general rule is that the
higher the generation of the test (e.g. 4th generation),
the shorter the serological ‘‘window period’’ between
the infection with HIV and its detection (Fig. 1) (CDC
2014).
In Belgium most clinical diagnostic laboratories
use 4th generation immunoassays. According to recent
data on the External Quality Assessment (EQA)
conducted by the Quality Department of the Medical
Laboratories of the Scientific Institute of Public Health
of 2016, 7/155 (4.5%) of Belgian diagnostic labora-
tories that took part in the EQA-cycle still use 3rd
generation immunoassays. Immunoassays belonging
to these two generations, 3rd and 4th, do not differ in
terms of the detection of anti-HIV 1/2. However, 4th
generation tests detect additionally p24 antigen of HIV
which means that the HIV-1 infection can be detected
before HIV antibodies can be detected.
It follows that using 3rd generation immunoassays
for serological screening in HBM donors means that
the ‘‘window period’’ will be 3–5 days longer com-
pared to the use of 4th generation anti-HIV-1/2 tests.
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Given the fact that the generation of the anti-HIV1/
2 immunoassay used affects the ‘‘window period’’ of
this test, which in turn impacts on the safety of the
donation, it is of paramount importance to use the tests
with the shortest ‘‘window period’’, i.e. 4th generation
tests.
In the event of non-negative (grey zone or reactive)
screening result for anti-HIV 1/2, and pending confir-
mation by an ARL, the report must clearly state that
these screening results still need to be confirmed. In
Belgium, the ARL’s are in charge of interpreting and
reporting the HIV confirmatory test results. The final
result of the test is that obtained by an ARL on the
basis of the confirmatory tests carried out.
HIV NAT testing
As was the case for serological assays, the analytical
features of NAT tests used for HIV screening have
evolved significantly over the past decade (Gullett and
Nolte 2015; Hopkins et al. 2015). At the methodolog-
ical level, almost every analytical feature of the NAT
tests for HIV has been optimized. As with regard of the
scope of the current recommendations, especially
improvement in sensitivity and accuracy, also in low
analytical range, is of importance.
Carrying out additional HIV NAT testing reduces
the ‘‘window period’’ after a possible HIV infection
with additional 3–4 days compared to the 4th gener-
ation anti-HIV 1/2 serological tests described above,
which enhances the safety of HBM donation.
For the interpretation of the results of the biological
tests for the detection of antibodies/RNA of HIV, see
Table 1.
Biological tests for the detection of HBV
antibodies/DNA
HBV serology
The diagnosis of HBV infection is based upon
interpretation of different serological markers. The
fact that multiple markers are available and that these
different markers display divergent patterns of appear-
ance/persistence/disappearance during the period fol-
lowing the initial infection results in a fairly complex
interpretation chart.
The R.D. of 28 September 2009 mentioned above
provides that the serology for hepatitis B must, at the
very least, include HBsAg and anti-HBc assays.
In addition, Annex VI, Section 1.3 of this R.D.
states that if, on the one hand, the anti-HBc test is
Fig. 1 Serological profile
in relation to ‘‘window’’-
periods for different
generations of anti-HIV 1,2
assays. Anti-HIV 1,2
antibodies against human
immunodeficiency virus
types 1, 2; Ag antigen
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positive whilst on the other, the HBsAg and HBV
NAT tests are both negative, an anti-HBs shall be
carried out. If the latter test is positive, this points to a
natural infection that has been cleared, which means
that the positive anti-HBc test is not a contraindication
for releasing the HBM for human application. This is a
possible explanation for positive screening results for
anti-HBc in areas with a low seroprevalence of
HBsAg, as is the case in Belgium. Only tests
measuring total anti-HBc are discussed in the current
recommendations as the ones used in Belgian diag-
nostic laboratories.
If the HBsAg test is negative and the anti-HBc and
anti-HBs tests are both positive, this may be due to a
past naturally acquired HBV infection with HBsAg
clearance.
However from a microbiological point of view,
false positive result for anti-HBc cannot be excluded.
The serological profile corresponding to negative
HBsAg and anti-HBs in combination with positive
anti-HBc (‘‘core only’’ HBV serology) is not explicitly
described in the Belgian legislation. In this case the
possible interpretations include naturally acquired
HBV infection with clearance of HBsAg or false
positivity for anti-HBc. Unlike the serological profile
described above, there is no serological evidence in
support of there being any immunity, as the anti-HBs
test is negative. Despite the extremely low infectious
risk associated with individuals with a ‘‘core only’’
serological profile (and negative HBVNAT), as a rule,
HBM donations from these donors should nonetheless
be rejected (CDC 2015a). In exceptional individual
cases, the HBM administrator may derogate from this
rule, but only after having consulted the laboratory
virologist and after having carried out a thorough risk
assessment in agreement with all the parties (including
transplanting medical doctor and patient) concerned.
Carrying out additional HBV NAT testing has
enhanced the safety of HBM donations, as these can
yield positive results just 1 week after the initial
infection, whilst screening based on the early sero-
logical marker for acute infection, viz. HBsAg,
displays a high degree of variability and depends,
among other things, on the viral inoculum, the route of
transmission and host factors and usually only yields
positive results at least 1 month after the initial
infection. For donated HBM, it is usually possible to
wait for the results of HBV NAT testing, and it is
essential to interpret the serological results in con-
junction with those of HBV NAT testing (Forne´s et al.
2015; Workowski et al. 2015).
For the interpretation of the results of the biological
tests for the detection of antibodies/DNA of HBV, see
Table 2.
Biological tests for the detection of HCV
antibodies/RNA
Anti-HCV
The most recent guidelines from both the Centers for
Disease Control and Prevention (CDC 2015b) and the
European Association for the Study of Liver (EASL
2018), favor anti-HCV as the first-line diagnosis of an
HCV infection. In the event of positive result for anti-
HCV, it is advised by both international guidelines to
search for HCV RNA.
Interpretation difficulties are mainly due to the
combination of a positive result for anti-HCV and a
negative result for HCV RNA.: this serological profile
may be attributable to a past HCV infection that has
subsequently cleared or to a false-positive anti-HCV
result.
Table 1 Interpretation of the results of the biological tests for the detection of HIV antibodies/RNA
Anti-HIV 1/2a HIV NAT Interpretation Consequence for the donation Further management
Positive Positive Infection with a detectable viral load Reject Inform APb
Positive Negative Infection with an undetectable viral load Reject Inform AP
Negative Positive Acute infection Reject Inform AP
Negative Negative No infection Release possible No further action
aNegative result in clinical diagnostic laboratory or confirmed negative/positive result in ARL
bAP attending physician
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Ideally, one of the following confirmatory strate-
gies will be chosen in the event of a suspected false-
positive result for HCV antibodies. The second
strategy is hereby the preferable one to confirm that
this is indeed a false-positive result.
1. the carrying-out of an additional serological assay
for anti-HCV based on a different method than the
original test. Repeat false-positive results are
known to be rather unlikely, especially if different
methods are used. Also, if additional testing yields
a negative result, this indicates that the result for
the initial serological assay was false-positive.
Given the fact that these different serological
methods also vary in terms of their specificity, the
competent laboratory virologist needs to be
consulted.
2. if the initial serological assay yields a low
analytical value, the result will probably be
false-positive. For the vast majority of serological
tests for anti-HCV, the analytical results will be
expressed as S/CO (Signal to cut-off ratios). For
some anti-HCV tests, the CDC have suggested an
analytical value below which the result can be
regarded as probably false-positive. For the most
recent anti-HCV tests, however, such a cut-off
value for potentially false-positive results has not
(yet) been verified.
HCV NAT testing
Given the fact that a considerable amount of time
elapses between the initial infection and the appear-
ance of anti-HCV, the use of HCV NAT testing has
enhanced the safety of HBM donations. It is estimated
that in about half of those with an acute HCV infection
and detectable HCV RNA, the search for anti-HCV
remains negative.
For the interpretation of the results of the biological
tests for the detection of HCV antibodies/RNA, see
Table 3.
Biological screening tests for syphilis
Recent epidemiological findings confirm that syphilis
is more common in people who have also contracted
HIV and hepatitis C. Conversely, increasingly
Table 2 Interpretation of the results of the biological tests for the detection of HBV antibodies/DNA
HBsAg Total
anti-HBc
Anti-
HBs
HBV
NAT
Interpretation Consequence for the
donation
Furthr
management
Positive Negative Negative Positive Early acute infection Reject Inform APa
Positive Negative Negative Negative Recent vaccination, acute infection or false-
positive HBsAg result
Reject Inform AP
Positive Positive Negative Negative Chronicb infection with undetectable viral
load
Reject Inform AP
Positive Positive Negative Positive Acute/chronicb infection with detectable viral
load
Reject Inform AP
Negative Positive Positivec Negative Past natural infection, immunity Release possible No further
action
Negative Positive Negative Positive Occultd infection Reject Inform AP
Negative Positive Negative Negative ‘‘core only’’ profilee Reject No further
action
Negative Negative Positive Negative Post-vaccination immunity Release possible No further
action
Negative Negative Negative Positive Acute infection or false-positive result for
HBV NAT
Reject Inform AP
aAP attending physician
bChronic infection is defined as persistence of HBsAg for[ 6 months
cC 10 International Units (IU)/liter (l) (Morbidity and Mortality Weekly Report 2011; Derouin et al. 2008)
dOccult infection is defined as negative result for HBsAg with presence of HBV DNA in blood or tissues
eSee further in the text interpretation of ‘‘core only’’ serological profile
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sophisticated serological and NAT tests have become
available in recent years to screen for HIV and
hepatitis B and C. This has allowed to shorten the
window period to such an extent that a positive
syphilis test retains but a very limited relative value as
an indicator for an increased risk of HIV and hepatitis
C (Marrazzo 2014; Gallego-Lezaun et al. 2015; Jansen
et al. 2015; Peterman et al. 2015; Reisner et al. 2015).
A validated testing algorithm must be applied to
exclude the presence of active infection with Tre-
ponema pallidum. A non-reactive test, specific or non-
specific, can allow tissues and cells to be released.
When a non-specific test is performed, a reactive result
will not prevent procurement or release if a specific
Treponema confirmatory test is non-reactive. A donor
whose specimen tests reactive on a Treponema-
specific test will require a thorough risk assessment
to determine eligibility for clinical use (EU 2006/17).
Serological tests for the detection of syphilis
The algorithms that are recommended for the sero-
logical investigation for syphilis are challenging due
to the inherent complexity of the applied methods. In
the serological diagnostics of syphilis classification in
non-treponemal and treponemal tests is used with
frequently challenging interpretations and need for the
supplementary confirmatory testing (Morshed 2014).
Non-treponemal tests are tests that search for IgG
and IgM directed against the lipids that are released
from the damaged human cells during an early stage of
the disease. Their goal is therefore to search for
antibodies to antigens that are not specific to an
infection with species of the genus Treponema, as
reflected in the term reaginic antibodies. The non-
specific nature of this category of serological tests is
also reflected in the fact that many other causes, such
as advanced age, pregnancy, various types of malig-
nant tumors, autoimmune diseases and other unrelated
infections may result in the formation of anti-lipoid
antibodies, thus generating false-positive results.
Consequently, a positive result obtained with a non-
treponemal test should always be confirmed by means
of a treponemal test. Moreover, non-treponemal tests
usually display a low sensitivity as regards the
detection of early syphilis, whilst the first positive
results are only obtained some 4–8 weeks after
infection. The tests belonging to this category have
mainly a diagnostic purpose as part of the therapeutic
follow-up of patients with syphilis. Thus, a declining
titre over a certain period of time is indicative of a
favourable response to treatment. As a rule, a
successful treatment leads to negative results for these
tests. The Venereal Diseases Research Laboratory
(VDRL) test and Rapid Plasma Reagin (RPR) test
belong to this group of non-treponemal tests used for
serological syphilis screening.
Treponemal tests are serological screening tests
that search for specific antibodies directed against
species of the genus Treponema. No distinction can be
made between the different treponematoses due to
immunological cross-reactions. These tests usually
remain positive after the initial infection, which means
that they cannot be used to monitor the response to
treatment or diagnose reinfections. Treponemal sero-
logical tests include the T .pallidum haemagglutina-
tion (TPHA) test, the T. pallidum particle
agglutination (TPPA) test, treponemal enzyme
Table 3 Interpretation of the results of the biological tests for the detection of HCV antibodies/RNA
Anti-HCV HCV NAT Interpretation Consequence for the donation Further management
Positive Positive Infection with a detectable viral load Reject Inform APa
Positive Negative Passed infection with an undetectable viral
load or false-positive result for anti-HCV
Rejectb Inform AP
Negative Positive Early infection Reject Inform AP
Negative Negative No infection Release possible No further action
aAP attending physician
bIn the event of a low analytical value, the result will probably be false-positive. For the vast majority of serological tests for anti-
HCV, the analytical results will be expressed as S/CO. For some anti-HCV tests, the CDC have suggested an analytical value below
which the result can be regarded as probably false-positive. For the most recent new anti-HCV tests, however, such a cut-off value for
potentially false-positive results has not (yet) been verified (CDC 2015b)
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immunoassays (EIA), chemiluminescence immunoas-
says (CLIA) and immunoblotting.
New developments, especially as regards the opti-
misation of treponemal immunoassays, offer new
possibilities due to the earlier detection of syphilis and
the shorter diagnostic window, but do not necessarily
simplify the assessment of the overall serological
picture.
According to recent international recommendations
(IUSTI 2014), different screening algorithms can be
used for serological syphilis screening:
• Only the treponemal screening test This screening
strategy is commonly used in European blood
banks and laboratories due to its potential for
large-scale automation. This algorithm identifies
both individuals in whom syphilis has been treated
successfully as well as those who have not
received any treatment. It is better suited to detect
the early stages of infection than the sole use of a
non-treponemal test. Given the fact that this
strategy is mainly used for populations with a
low prevalence of syphilis, it is fraught with a
considerable number of false-positive results.
• Only the non-treponemal screening test Ideally, a
non-treponemal test carried out for screening
purposes should be quantitative in nature in order
to rule out the prozone effect when using undiluted
blood samples (this concerns\ 2% of samples,
usually during the secondary phase of syphilis.
These patients display extremely high titres of
antibodies that interfere with the formation of
antigen–antibody complexes, which are necessary
to visualise flocculation when interpreting the non-
treponemal test). This algorithm can only detect
active (infectious) syphilis, which means that it
can miss the early stage of syphilis.
• Treponemal and non-treponemal tests This algo-
rithm is especially useful to screen high-risk
populations as well as to screen for the early
stages of syphilis.
In the serological diagnosis of syphilis and inde-
pendently of the screening algorithm used, a confir-
matory test will always need to be carried out,
regardless of which of the screening tests turned out
positive.
• If the initial screening test only included a
treponemal test, the results should be confirmed
by means of a second treponemal test based on a
different analytical method as well as a quantita-
tive non-treponemal test if this second treponemal
test also turns out positive.
• If the initial screening test only included a non-
treponemal test, the positive result needs to be
confirmed by means of a treponemal test, whereas
the non-treponemal test should be performed in a
quantitative manner if this was not initially the
case.
• If the initial screening was performed using a
treponemal test as well as a non-treponemal test,
the non-treponemal test should be performed in a
quantitative manner. A second treponemal test
based on a different analytical method may be used
to rule out a false-positive result for the initial
treponemal test only if the non-treponemal test is
negative.
It seems advisable to carry out treponemal tests
(alone or in combination with non-treponemal tests)
during the initial screening that is carried out as part of
the process of HBM donations to ensure maximum
safety for the HBM intended for donation.
For the interpretation of the results of the biological
tests for the serological detection of syphilis, see
Table 4.
Optional biological tests
Based on the European Directives a number of tests
are mandatory however the application in different
European countries is variable as demonstrated in EU
mapping of blood donor testing requirements 2015.
From this survey Belgium is a safe country for HBM
transplantation. Optional tests can always be per-
formed but the implication on the availability of HBM
should be kept in mind.
The R.D. of 28 September 2009 mentioned above
provides that further biological testing is required
under specific circumstances. The criteria that are
crucial when selecting possible additional tests have to
do with the donor’s medical history and specific
features of the donated HBM. This paper looks at
screening for HTLV-1 antibodies, CMV, toxoplasmo-
sis and EBV as examples for such additional serolog-
ical tests.
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The decision to run these optional tests is made on
the basis of the tissues and cells that are intended for
donation as well as specific clinical and epidemiolog-
ical circumstances.
Infections are transmitted most effectively via
viable cells and tissues, blood, stem cells and vascu-
larized organs. In addition the risk might be greater if
the recipient is immunocompromised and the HBM
has not undergone a decontamination procedures
(Fishman et al. 2012).
Biological tests for the detection of antibodies/
DNA of Toxoplasma gondii
Anti-toxoplasma
Serological tests for the detection of anti-Toxoplasma
IgG and IgM belong to routine testing in the most
clinical diagnostic laboratories in Belgium. There is a
profound commercial offer available on the diagnostic
market. In general, the anti-Toxoplasma IgG does not
pose any significant analytical problems, whereas the
search for anti-Toxoplasma IgM is subject to possible
cross-reactivity with other acute unrelated infectious
processes (e.g. acute CMV or EBV infections) or
autoimmune diseases outcoming in false positive
results (Roberts et al. 2001; Kodym et al. 2007). In
recent years, laboratories have acquired considerable
expertise in the use of Toxoplasma IgG-avidity tests
that are not fraught with specificity problems that are
typical of IgM assays (Lappalainen and Hedman 2004;
Sensini 2006; Candolfi et al. 2007; Villard et al. 2013).
Molecular assays for the identification of Toxo-
plasma DNA are rarely, if at all, performed as part of
the HBM donation process in particular and in general
for the confirmation of active infection in Belgian
clinical diagnostic laboratories. Since requests for
Toxoplasma gondii genome screening are very rare,
this assay is not widely available in Belgian diagnostic
laboratories. It is almost exclusively carried out as part
of the screening/confirmatory process of ocular or
congenital toxoplasmosis.
For the interpretation of the results of the biological
tests for the detection of antibodies against Toxo-
plasma gondii, see Table 5.
Biological tests for the detection of EBV
antibodies/DNA
Anti-EBV
Most Belgian diagnostic laboratories already routinely
use serological testing to screen for both specific and
non-specific antibodies to EBV. There is a broad
commercial offer available that allows to search for a
wide range of parameters, thus contributing to a more
Table 4 Interpretation of the results of the biological tests for the serological detection of syphilis
Treponemal
test
Non-treponemal
test
Interpretation Consequence for
the donation
Further
management
Positive Positivea Active infection Reject Inform APb
Positive Negative (Treated) past infection or early infection of false-positive
treponemal test
Rejectd Inform APc
Negative Not carried out
or negative
No infection Release possible No further
action
Negative Positive False-positive result for the non-treponemal test or false-
negative result for the treponemal test
Release
potentially
possibled
No further
action
aGiven the fact that in the vast majority of cases in which non-treponemal tests yielded false-positive results, the titre were B 1/4; a
‘‘positive non-treponemal test’’ is considered to be a test with a titre of C 1/8
bAP attending physician
cIn this serological situation confirmatory treponemal test should be performed. In case of negativity of confirmatory treponemal test,
is the initial positive screening for treponemal test seen as false positive, justifying HBM release; no contact with AP is required
dThe bank administrator can still accept the HBM after having consulted the pathologist, possible after carrying out additional tests
(quantitative non-treponemal test; additional treponemal test) and after having received the informed consent of the recipient and the
medical transplant team
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accurate interpretation. These parameters as well as
the testing algorithms differ from one diagnostic
laboratory to another. The following serological
parameters can be searched for in order to establish
the serological progress of the EBV infection and
especially to detect/rule out an acute infection: non-
specific heterophile IgM antibodies (anti-HA IgM),
IgM antibodies to viral capsid antigens (anti-VCA
IgM), IgG antibodies to viral capsid antigens (anti-
VCA IgG), IgG antibodies to EBV nuclear antigens
(anti-EBNA IgG) and IgG antibodies to EBV early
antigens (anti-EA IgG) (Fig. 2). The commercially
available serological tests that are commonly used to
search for anti-EBV IgG do not present any significant
analytical problems, whereas anti-EBV IgM screening
tests have to contend with a considerable number of
false-positive results, mainly as regards patients with
acute infections with taxonomically related herpes
viruses (e.g. CMV, Varicella Zoster virus). (Gulley
and Tang 2008; Neocleous et al. 2013; De Paschale
and Clerici 2012).
Molecular assays for the identification of EBV
DNA are rarely, if ever, performed as part of the HBM
donation process. The same is true for Belgian
diagnostic laboratories. These assays are usually only
carried out as part of the screening and follow-up
process of patients who are at an increased risk of post-
transplant lymphoproliferative disease (PTLD).
Each individual diagnostic laboratory is responsi-
ble for determining which test combinations they will
use to detect acute/past EBV infections and reactiva-
tions. The tests mentioned above do not always need to
be carried out.
Table 5 Interpretation of the results of the biological tests for the detection of antibodies against Toxoplasma gondii
Anti-toxoplasma
IgG
Anti-toxoplasma
IgM
Interpretation Consequence for the
donation
Further
management
Positive Positive Acute infection or false-positive IgM
result
Reject Inform APa
Negative Positive Acute infection or false-positive IgM
result
Reject Inform AP
Positive Negative Past infection Release possible No further action
Negative Negative No infection Release possible No further action
aAP attending physician
Fig. 2 Serological
progression of EBV
infection in relation to
detection of antibodies to
different EBV antigens. HA
IgM heterophilic IgM
antibodies; anti-VCA IgM
IgM antibodies against viral
capsid antigen; anti-VCA
IgG IgG antibodies against
viral capsid antigen; anti-
EBNA IgG IgG antibodies
against EBV nuclear
antigen; anti-EA IgG IgG
antibodies against EBV
early antigen
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For the interpretation of the results of the biological
tests the detection of antibodies against EBV, see
Table 6.
Biological tests for the detection of HTLV
Directive 2012/39/EU requires that HTLV-1 antibody
tests be carried out in certain circumstances: in the
case of living donors living in or originating from
regions with a high prevalence or whose sexual partner
or parents come from such regions.
Most of the serological tests that are currently
available on the market detect anti-HTLV-1 and
HTLV-2 antibodies. They use recombinant antigens
and/or synthetic peptides, which enhances their
specificity compared to that of first generation tests.
Nevertheless, the positive predictive value of these
tests remains low, especially in low-prevalence pop-
ulations. A confirmatory immunoblot must therefore
be carried out for all positive screening tests. A
positive immunoblot confirms the diagnosis, whilst a
negative immunoblot rules out an HTLV-1/2 infec-
tion. In some cases, the result may be indeterminate,
i.e. there is reactivity to one or several HTLV-
antigens, whilst the criteria for positivity are not met.
This is a common situation (up to 50% of cases) in
endemic areas and may indicate early seroconversion.
It rarely occurs in Belgium, which has a very low
seroprevalence (\ 0.1%) (Costa et al. 2011; ECDC
2012a, b; Marano et al. 2016).
In this respect, molecular biology techniques (NAT
tests) play only a very marginal role, as the latter do
not confer any advantages in terms of sensitivity,
specificity and cost.
Some studies reveal that the sensitivity of the
immunoblot is superior to that of NAT testing in the
diagnosis of HTLV-1/2 infection in the event of a
positive screening test result. One explanation for the
lower sensitivity of NAT testing in this context is the
low viral load displayed by some asymptomatic
individuals (Costa et al. 2011).
For the interpretation of the results of the biological
tests for the detection of anti-HTLV-1, see Table 7.
Biological tests for the detection of CMV
During CMV primary infection, the virus spreads via
polymorphonuclear cells and monocytes and after-
wards remains for life, mainly in endothelial cells,
bone-marrow progenitor cells, and circulating mono-
cytes. Under certain circumstances, such as the stem
cell or sperm donations, serological testing for CMV is
required. The tests used detect anti-CMV IgG and
IgM.
Screening for anti-CMV IgG allows to identify
donors carrying CMV, which is true for 50% of the
Table 6 Interpretation of the results of the biological tests for the detection of antibodies against EBV
Heterophile
antibodies
Anti-
VCA
IgM
Anti-
VCA
IgG
Anti-
EBNA
IgG
Anti-EA
IgG
Interpretation Consequence
for the donation
Further
management
Positive Positive Negative Negative Positive Early acute infection Rejecta Inform APb
Positive Positive Positive Negative Positive Acute infection/early recovery Rejecta Inform AP
Positive Negative Negative Negative Negative Early acute infection or false-positive
result for heterophile antibodies
Rejecta Inform AP
Negative Positive Negative Negative Negative Early acute infection or false-positive
result for anti-VCA IgM
Rejecta Inform AP
Negative Negative Positive Negative Positive Recovery Release
possible
No further
action
Negative Negative Positive Positive Positive Recovery Release
possible
No further
action
Negative Negative Positive Positive Negative (past) infection Release
possible
No further
action
aOnly if seronegative recipient
bAP attending physician
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population in countries with high socio-economic
standards such as Belgium. Detecting anti-CMV IgG
poses few interpretation problems, except for equiv-
ocal results, i.e. in the grey zone of the test. In that
case, it is possible to run a second IgG test, viz. one
that is based on a different analytical method, but if
any doubt remains, the donor should be considered as
CMV positive.
IgM tests are less specific and their interpretation
often poses problems when there is no suggestive
clinical presentation. Indeed, the presence of anti-
CMV IgM is not necessarily linked to a recent
infection. Positive results can also be due to cross-
reactions with other herpes viruses such as Epstein–
Barr virus or another infection leading to non-specific
polyclonal stimulation of the immune system. In
addition, the use of increasingly sensitive techniques
makes it possible to detect specific IgM antibodies
long after the onset of primary infection (FDA 2007;
Kotton et al. 2013).
Analogous with use of Toxoplasma IgG avidity
testing, avidity testing for CMV IgG can be applied in
certain clinical situations in case of positivity for anti-
CMV IgG as well as anti-CMV IgM. Current poor
standardization of avidity testing for CMV IgG has to
be kept in mind (Revello et al. 2010).
In case of doubt, confirmation using molecular
techniques seems justified, given the fact that clinical
laboratories are experienced in carrying out molecular
assays on blood/plasma samples, though not as part of
the diagnosis of acute infection. These findings imply
that it is necessary to consult with the competent
laboratory virologist if the decision is made to carry
out a molecular assay.
For the interpretation of the results of the biological
tests the detection of antibodies against CMV, see
Table 8.
Other tests
Depending on the travel history and specific current or
past clinical situation of the HBM donor as well as the
ongoing epidemiological situation and the nature of
the HBM intended for donation, the decision can be
made to carry out other optional tests, such as
screening for tropical infections such as malaria,
trypanosomiasis, infections with the West Nile virus,
Zika virus, etc. The need to perform such assays, or
Table 8 Interpretation of the results of the biological tests for the detection of antibodies against CMV
Anti-CMV
IgG
Anti-CMV
IgM
Interpretation Consequence for the
donation
Further
management
Positive Positive Acute infection or false-positive result for
IgM
Release possiblea Inform APb
Negative Positive Acute infection or false positive result for
IgM
Release possiblea Inform AP
Positive Negative Old infection Release possible No futher action
Negative Negative No infection Release possible No further action
aDepending on the type of donation and the serostatus of the recipient
bAP attending physician
Table 7 Interpretation of the results of the biological tests for the detection of antibodies against HTLV-1
Anti-HTLV-1 screening Anti-HTLV-1 immunoblot Interpretation Consequence for the donation Further management
Negative Not carried out No infection Release possible No further action
Positive Negative No infection Release possible No further action
Positive Indeterminate Possible infection Reject Inform APa
Positive Positive Infection Reject Inform AP
aAP attending physician
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even others, must be examined on a case-by-case
basis.
Discussion
A number of practical recommendations have been
formulated with the intention to make progress in the
standardization of in particular testing, interpretation
of biological tests on blood samples of potential
donors of human body material. Better and more
standardized interpretation of sometimes challenging
results of biological tests will facilitate their use,
promote communication between banks of human
body material and clinical diagnostic laboratories, and
will finally increase the safety of donation. On the
other hand the correct evaluation of (a combination of)
results of biological tests will diminish the number of
rejected potential donors due to too strict interpreta-
tion of individual tests.
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